Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Partially Remote
Drugs
Locations
Clinical Specialty
481-500 of 998 trials

Thyroid Eye Disease: Sirolimus vs. Corticosteroids

We are comparing a new treatment called Sirolimus with corticosteroids for people with active thyroid eye disease. The goal is to see if Sirolimus is more effective and has fewer side effects.

Thyroid Eye Disease≤3 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteEndocrinologyOphthalmology

Long-Term Study of Galapagos CAR T-Cell Therapies

We are evaluating the long-term safety and effectiveness of Galapagos CAR T-cell therapies in patients. This study aims to understand how these treatments work over many years.

Relapsed/Refractory B-Cell Non-Hodgkin LymphomaRelapsed/Refractory Multiple MyelomaRelapsed/Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)>2 yearsConfirmation phase (III)16-20 visitsNo PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Takotsubo Syndrome: Beta-Blockers Study

We are investigating whether beta-blockers can help improve heart function in patients with Takotsubo Syndrome. This study will also look at various heart health measures and quality of life.

Takotsubo Syndrome1-2 yearsMonitoring phase (IV)6-10 visitsPartially RemoteCardiologyInternal Medicine

GSDIa: DTX401 Treatment Study

We are examining the long-term safety and pregnancy outcomes of DTX401 for individuals with GSDIa. This study will help us understand how effective this treatment is over time.

Glycogen Storage Disease Type IA>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboInvestigational MedicinesPartially RemoteEndocrinologyInternal Medicine

Solid Tumors: E7386 with Other Anticancer Drugs

We are studying the safety and effectiveness of E7386 combined with other anticancer treatments for patients with solid tumors. This trial aims to find the best dose and assess how well it works compared to standard therapies.

Liver Cancer (Hepatocellular Carcinoma)Colorectal CancerEndometrial CancerSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Niemann-Pick Disease Type C: N-Acetyl-L-Leucine Study

We are investigating whether N-Acetyl-L-Leucine can improve symptoms and quality of life for individuals with Niemann-Pick disease type C. The study also looks at the safety of this treatment for both older and younger patients.

Niemann-Pick Disease Type C3-6 monthsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteHematologyNeurology

Chronic Lymphocytic Leukemia: Venetoclax and Pirtobrutinib Study

We are comparing different treatment plans for newly diagnosed chronic lymphocytic leukemia patients to see if a personalized approach improves outcomes. This includes assessing how long patients can stay in remission and the overall effectiveness of the treatments.

Chronic Lymphocytic Leukaemia (CLL)Small Lymphocytic Lymphoma (SLL)>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesPartially RemoteHematologyOncology

Head and Neck Cancer: Petosemtamab Treatment Study

We are studying the effects of petosemtamab in patients with advanced head and neck cancer who have not responded to previous treatments. The goal is to see if it improves survival and tumor response compared to standard therapies.

Metastatic Head and Neck Squamous Cell Carcinoma>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Head and Neck Cancer: Petosemtamab with Pembrolizumab

We are studying a new treatment combination for patients with recurrent or metastatic head and neck cancer to see if it works better than standard treatment. This trial is for those with tumors that express PD-L1.

Metastatic Squamous Cell Carcinoma of the Head and Neck>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteOncology

Paroxysmal Nocturnal Hemoglobinuria: Pozelimab and Cemdisiran Therapy

We are studying the long-term safety and effectiveness of a combination therapy for adults with Paroxysmal Nocturnal Hemoglobinuria. This trial will help us understand its impact on symptoms like fatigue and hemoglobin levels.

Paroxysmal Nocturnal Hemoglobinuria>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyInternal Medicine

Hypereosinophilic Syndrome: Depemokimab Study

We are investigating whether Depemokimab can help adults with Hypereosinophilic Syndrome manage their symptoms better than a placebo. This study aims to provide insights into its effectiveness and safety.

Hypereosinophilic Syndrome1-2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteHematologyInternal Medicine

Myotonic Dystrophy Type 1: DYNE-101 Treatment Study

We are evaluating the safety and effects of a new treatment, DYNE-101, for people with Myotonic Dystrophy Type 1. The study aims to see how it impacts muscle health and overall well-being.

Myotonic Dystrophy>2 yearsSafety phase (I)Efficacy phase (II)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteNeurologyOrthopedics and Traumatology

Severe Diffuse Cutaneous Systemic Sclerosis: Rapcabtagene Autoleucel vs. Rituximab

We are studying a new treatment to see if it works better than rituximab for people with severe diffuse cutaneous systemic sclerosis. The trial will also evaluate the safety of this new therapy.

Systemic Scleroderma1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

Multiple Myeloma: Teclistamab with Lenalidomide

We are studying a new treatment combining teclistamab and lenalidomide for patients with newly diagnosed multiple myeloma after stem cell transplant. The aim is to see if this combination works better than lenalidomide alone in maintaining remission.

Newly Diagnosed Multiple MyelomaConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyOncology

Cirrhosis Treatment: Pegozafermin Study

We are studying a new medication, pegozafermin, for individuals with compensated cirrhosis due to MASH. The goal is to see if it can improve liver health and reduce related health risks compared to a placebo.

Chronic Liver Disease and Cirrhosis>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyHepatology

Brivaracetam for Childhood Absence Epilepsy

We are studying whether brivaracetam is effective and safe for children and young adults aged 2 to 25 with childhood or juvenile absence epilepsy. This trial aims to provide insights into its use as a standalone treatment.

Childhood Absence Epilepsy3-6 monthsEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

HER2-Altered Cancers: Zongertinib Study

We are testing whether zongertinib can help people with advanced solid tumors that have HER2 mutations or overexpression. The study will evaluate its effectiveness, safety, and how patients respond to the treatment.

HER2-mutated or overexpressed/amplified solid tumorsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Septic Shock: Levetiracetam Treatment Study

We are studying whether early treatment with levetiracetam can help patients with septic shock stay awake and alert. The trial also examines its effects on survival and overall quality of life.

Septic Shock>2 yearsConfirmation phase (III)Standard MedicinesCost ReimbursementPartially RemoteInfectious DiseasesInternal MedicineNeurologyPulmonology

Uncontrolled Asthma: Dupilumab vs. High Dose ICS

We are studying whether adding dupilumab to medium dose asthma medication helps reduce severe asthma attacks better than increasing the dose of current treatments. This trial is for adolescents and adults with uncontrolled asthma.

Asthma1-2 yearsMonitoring phase (IV)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteAllergologyPulmonology

Crohn's Disease: AZD7798 Treatment Study

We are investigating how well AZD7798 works and its safety for people with moderate to severe Crohn's disease. This study will help us understand its effects on disease activity and overall health.

Crohn's Disease1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterology